Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit: Investors Face April 6, 2026, Deadline
Rhea-AI Summary
Positive
- None.
Negative
- None.
News Market Reaction – RARE
On the day this news was published, RARE gained 0.70%, reflecting a mild positive market reaction. This price movement added approximately $15M to the company's valuation, bringing the market cap to $2.20B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
RARE was up about 1% while close peers showed mixed, mostly modest moves (e.g., XENE up 3.32%, SLNO down 0.61%). No momentum‑scanner peers were flagged, pointing to a stock‑specific backdrop rather than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Investor conferences | Neutral | -0.9% | Participation in three March investor conferences with webcast access. |
| Feb 23 | Regulatory milestone | Positive | -0.9% | FDA acceptance and Priority Review of DTX401 BLA with PDUFA date set. |
| Feb 20 | Inducement grants | Neutral | +3.3% | Issuance of 22,917 RSUs to new non‑executive officers under inducement plan. |
| Feb 13 | Class action notice | Negative | -12.7% | Notice of April 6, 2026 lead‑plaintiff deadline for class action lawsuit. |
| Feb 12 | Earnings and guidance | Neutral | -1.6% | Report of 2025 results, 2026 revenue guidance, and restructuring with workforce cuts. |
Recent history shows occasional selloffs on positive regulatory news and sharp declines on legal headlines.
Over the last few months, Ultragenyx reported strong 2025 revenue of $673 million but a sizeable $575 million net loss and announced restructuring, with shares slipping modestly afterward. An earlier class action headline on Feb 13 coincided with a steep -12.68% move, highlighting market sensitivity to legal risk. Positive regulatory milestones, such as FDA Priority Review for DTX401 on Feb 23, were followed by a small decline, suggesting investor caution despite pipeline progress.
Market Pulse Summary
This announcement highlights a securities‑fraud class action covering trades between August 3, 2023, and December 26, 2025, focused on disclosures about setrusumab and Phase 3 fracture‑rate endpoints. It follows earlier recognition that the Orbit and Cosmic studies did not meet primary efficacy goals and a sharp stock decline to $19.72 in December 2025. Investors may track lawsuit progress, any further UX143 analyses, and how legal developments intersect with Ultragenyx’s broader rare‑disease pipeline and recent regulatory milestones.
Key Terms
securities fraud class action lawsuit regulatory
lead plaintiff regulatory
annualized fracture rate medical
placebo control group medical
AI-generated analysis. Not financial advice.
Did you buy RARE common stock between August 3, 2023, and December 26, 2025?
Affected Ultragenyx Pharmaceutical Inc. Investor Summary
- Who: Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
- What: Securities fraud class action lawsuit filed
- Class Period: August 3, 2023, through December 26, 2025
- Deadline to Seek Lead Plaintiff Status: April 6, 2026
- Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's drug, setrusumab
- Investor Action: Contact Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) for recovery options at no cost to investor
RADNOR, Pa., Feb. 24, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (Ultragenyx) (NASDAQ: RARE) on behalf of those who purchased or acquired Ultragenyx common stock between August 3, 2023, and December 26, 2025, inclusive. The lawsuit is filed in the United States District Court for the Northern District of California and is captioned Bailey v. Ultragenyx Pharmaceutical Inc., et al, Case No. 3:26-cv-01097 (N.D. Cal.). Investors have until April 6, 2026, to file for lead plaintiff status.
CONTACT KTMC TO DISCUSS YOUR LEGAL RIGHTS:
If you purchased or acquired Ultragenyx Pharmaceutical Inc. common stock and have lost money on your investment, you are encouraged to contact KTMC attorney Jonathan Naji, Esq. at:
(484) 270-1453
info@ktmc.com
https://www.ktmc.com/rare-ultragenyx-pharmaceutical-inc-class-action-lawsuit?utm_source=PR_Newswire&utm_medium=pressrelease&utm_campaign=rare&mktm=PR
There is no cost or obligation to speak with an attorney.
ULTRAGENYX PHARMACEUTICAL INC. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ultragenyx created the false impression that they possessed reliable information pertaining to the effects of the company's drug, setrusumab, on patients with variable types of Osteogenesis Imperfecta, while also minimizing risk that patients in Ultragenyx's Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate ("AFR"), such that the second interim analysis could be performed and presented to the investing public; (2) in truth, Ultragenyx's optimism in the Phase III Orbit study's results and interim analysis benchmark were misplaced because Ultragenyx failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and thus had not ruled out that the reduction in AFR from that study could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment; and (3) as a result, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Why did Ultragenyx's Stock Drop?
On December 29, 2025, Ultragenyx shocked the market when it revealed that both its Phase III Orbit and Cosmic studies had not "achieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively." On this news, Ultragenyx's stock price fell over
WHAT RARE INVESTORS CAN DO NOW:
- File to be lead plaintiff by April 6, 2026.
- Contact KTMC for a free case evaluation.
- Retain counsel of choice or take no action.
THE LEAD PLAINTIFF PROCESS FOR ULTRAGENYX PHARMACEUTICAL INC. INVESTORS:
Ultragenyx investors may, no later than April 6, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.
Kessler Topaz Meltzer & Check, LLP encourages Ultragenyx investors to contact the firm for more information.
ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP (KTMC):
Kessler Topaz Meltzer & Check, LLP (KTMC) is a leading U.S. plaintiff-side law firm focused on securities-fraud class actions and global investor protection. The firm represents individual investors as well as institutions, such as major pension funds, asset managers, and international investors. KTMC has led some of the largest recoveries in securities litigation and has been recognized by peers and the legal media with numerous accolades, including The National Law Journal's Plaintiff's Hot List and Trailblazers in Plaintiffs' Law, BTI Consulting Group's Honor Roll of Most Feared Law Firms, The Legal Intelligencer's Class Action Firm of the Year, Lawdragon's Leading Plaintiff Financial Lawyers, and Law360's Titans of the Plaintiffs Bar. The firm operates globally with offices in Pennsylvania and California. KTMC has recovered over
CONTACT:
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
info@ktmc.com
May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ultragenyx-pharmaceutical-inc-rare-class-action-lawsuit-investors-face-april-6-2026-deadline-302696309.html
SOURCE Kessler Topaz Meltzer & Check, LLP
